GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD - Toronto, ON, Canada

Video navigation menu

Design and primary results of the LEADER and SUSTAIN-6 GLP-1RA outcome trials 0:31
Patients with peripheral artery disease (PAD) are at higher CV risk, also in the GLP-1RA outcome trials 1:40
Treatment effect of GLP-1RA therapy in T2DM patients with PAD 4:19
RIsk and GLP-1RA treatment benefit in T2DM patients with concomitant CAD and PAD 6:50

Educational information

This video was recorded at the AHA in Philadelphia, USA, on November 17, 2019

Faculty

Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, Ont, Canada

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.